⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436261 | 1.00 | — | — | |
| SCHEMBL3830497 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5709800 | 0.98 | FDPS (0.42) | — | |
| SCHEMBL24531742 | 0.94 | FDPS (0.50) | — | |
| SCHEMBL19820361 | 0.94 | FDPS (0.50) | — | |
| SCHEMBL3086112 | 0.94 | FDPS (0.50) | — | |
| Hydrochloric Acid SCHEMBL31436221 | 0.92 | FDPS (0.49) | — | |
| Hydrochloric Acid SCHEMBL29642935 | 0.92 | FDPS (0.49) | — | |
| Hydrochloric Acid SCHEMBL5709804 | 0.92 | FDPS (0.49) | — | |
| Trifluoroacetic Acid SCHEMBL30017784 | 0.88 | FDPS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | claimed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115380030-A | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| US-20090131508-A1 | Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug | UCB PHARMA, S.A. (BE) | 2009-05-21 | — | — | US | disclosed |
| EP-1536783-B1 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PFIZER ITALIA SRL (IT) | 2008-08-06 | — | — | EP | disclosed |
| EP-1893193-A2 | USE OF BRIVARACETAM FOR THE TREATMENT OF DISEASES CHARACTERIZED BY PROGRESSIVE MYOCLONIC EPILEPSY | UCB Pharma, S.A. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006131322-A2 | USE OP BRIVARACETAM FOR THE TREATMENT OF DISEASES CHARACTERIZED BY PROGRESSIVE MYOCLONIC EPILEPSY | UCB PHARMA, S.A. (BE) | 2006-12-14 | — | — | WO | disclosed |
| EP-1731149-A1 | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy | UCB S.A. (BE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
| CN-1190963-A | 2-amino-benzoxanones for the treatment of viral infections | SEARLE & CO (US) | 1998-08-19 | — | — | CN | disclosed |